| |
Word from our CEO
As we begin a new year, I want to pause and recognize something truly extraordinary. Myeloma Canada’s Giving Tuesday fundraising campaign surpassed every expectation, raising an incredible $95,000. What unfolded was more than fundraising success. It was a powerful expression of trust, urgency, and collective resolve from you, the myeloma community.
Read Martine's full message.
| | |
In this issue...
- Our Takeaways from ASH 2025: Real Progress and Growing Momentum in Myeloma Research
- Patient Perspectives, Access to Treatment, and Navigating Complex Systems: A Look Back on a Year of Advocacy
- InfoConferences: Saint-Jean-sur-Richelieu, QC, Victoria, BC, Kelowna, BC, Drummondville, QC, and Brampton, ON
- Survey on IsaVRd : isatuximab + bortezomib + lenalidomide + dexamethasone
- New video: Pesticides et les cancers du sang, quels liens?
- Spotlight on Bonnie Hall
| |
Our Takeaways from ASH 2025: Real Progress and Growing Momentum in Myeloma Research
Myeloma Canada representatives joined thousands from the global hematology community at the 67th American Society of Hematology (ASH) annual meeting in December 2025, the largest hematology meeting in the world. Researchers and clinicians from around the globe shared important new findings in myeloma research.
Our takeaways from ASH 2025
| | |
Patient Perspectives, Access to Treatment, and Navigating Complex Systems: A Look Back on a Year of Advocacy
In 2025, Myeloma Canada continued to advocate for a healthcare system where innovation, compassion, and equity come together to serve people living with cancer.
Learn more about our 2025 advocacy activities.
| | | |
InfoConference
Myeloma Canada is coming to Victoria, BC, to share information and resources for Canadians affected by myeloma.
Date: February 26, 2026
Register now!
| | |
Upcoming InfoConferences
Stay tuned for these upcoming InfoConferences in March:
Saint-Jean-sur-Richelieu, QC (in French): February 25
Kelowna, BC: March 12
Drummundville, QC (in French): March 16
Brampton, ON : March 23
Save the date!
| | Reminders and Announcements | | |
Have your voice heard!
A new combination of myeloma drugs, IsaVRd, is under review for reimbursement as induction therapy before autologous stem cell transplant (ASCT) in individuals with newly diagnosed transplant-eligible myeloma.
Deadline: January 28, 2026
Learn more and respond.
| | |
New video: Pesticides et les cancers du sang, quels liens?
Watch the latest webinar (in French) to hear from Pascal Priori, M. Sc, from Victimes des pesticides du Québec and the Association pour la santé publique du Québec (ASPQ).
Watch the recording.
| | |
ASCO and Cancer Care Ontario Publish Myeloma Treatment Guidelines
These updates address four key domains:
- therapeutic decision-making in smoldering myeloma
- considerations around transplant-eligibility and post-transplant consolidation/maintenance therapy
- treatment of transplant-ineligible patients with NDMM
-
treatment of relapsed/refractory myeloma.
Learn more.
| | |
Continuing Medical Education for Primary Care Providers
Myeloma Canada has partnered with Queen’s University to develop an on-demand, accredited CME learning program:
- 5 self-assessment learning hours for the Royal College;
- 5 mainpro+ credits in the Self-Learning Category for the CFPC;
- certificate for 1.5 hours of professional development for all health professions.
Learn more.
| | | |
Spotlight on Bonnie Hall
My name is Bonnie Hall, and this is my story. I am a myeloma patient, or as I like to think of myself, a Myeloma Warrior. Most people want to know how I knew something was wrong in the beginning, so let’s start there. In the months leading up to my diagnosis, I had been feeling incredibly tired, a different tired than I had ever experienced before.
Read Bonnie's story.
| | |
A Note of Thanks on Behalf of Myeloma Canada
Thank you to everyone who donated in December 2025. Your generosity truly surpassed any expectations. We are deeply grateful for the trust you have placed in us and for standing so strongly with the myeloma community. Your support is making a meaningful difference, and we are honoured to carry this mission forward with you.
| | | | |
Myeloma Canada's mission: To improve the lives of all Canadians affected by myeloma by accelerating access to the best care while advancing research toward its cure and prevention.
Follow us on social media for the most up-to-date information and resources:
| | |
Si vous préférez recevoir vos communications en français, écrivez-nous à contact@myelome.ca.
To donate to Myeloma Canada please visit myeloma.ca or call us toll-free at 1-888-798-5771.
|
| Myeloma Canada charitable number: 862533296RR0001 | | | | | |
